LIF1 Antibody

What is Leukemia Inhibitory Factor and what are its primary functions?

Leukemia Inhibitory Factor is a 202-amino acid residue protein encoded by the LIF gene in humans. It functions as a member of the IL-6 cytokine family that activates downstream signaling pathways by binding to the heterodimeric receptor complex consisting of LIFR and gp130 on the cell surface. LIF is involved in multiple biological processes including immune response regulation and lung development. The protein is secreted and features glycosylated post-translational modifications. Other synonyms for this cytokine include CDF, DIA, and HILDA . LIF plays critical roles in various contexts including stem cell maintenance, cancer progression, and inflammatory responses .

How do LIF antibodies facilitate research applications?

LIF antibodies enable researchers to perform antigen-specific immunodetection of LIF in biological samples through various techniques. Western blot represents one of the most widely used applications, allowing for protein expression analysis and quantification. Additionally, ELISA techniques provide sensitive quantitative detection of LIF in experimental samples . These antibodies serve as essential tools for investigating LIF's role in various physiological and pathological processes, including cancer research, stem cell biology, and developmental studies .

What are the typical reactivity profiles of commonly available LIF antibodies?

Most commercially available LIF antibodies demonstrate species-specific reactivity profiles. While some antibodies are species-restricted (such as those specific to mouse LIF), others exhibit cross-reactivity across multiple species. For example, the antagonist antibody 1G11 has demonstrated excellent binding activity to human, cynomolgus monkey, and mouse LIF, making it particularly valuable for translational research . When selecting an appropriate antibody, researchers should verify the specific reactivity profile to ensure compatibility with their experimental model system .

What are the differences between polyclonal and monoclonal LIF antibodies?

Polyclonal LIF antibodies, such as those from MyBioSource, recognize multiple epitopes on the LIF protein, providing robust detection capabilities but potentially lower specificity. In contrast, monoclonal antibodies recognize a single epitope, offering higher specificity but potentially reduced sensitivity compared to polyclonal options. The choice between these antibody types depends on the specific research application. For epitope mapping or blocking studies, monoclonal antibodies like 1G11 offer precise targeting of functional domains on LIF , while polyclonal antibodies may be preferable for applications requiring stronger signal detection .

How can LIF antibodies be utilized in cancer research?

LIF is highly expressed in various tumor tissues including pancreatic, breast, prostate, and colorectal cancers, where it promotes cancer cell proliferation, migration, invasion, and differentiation. Antagonist antibodies targeting LIF, such as 1G11, have demonstrated significant anti-tumor effects in preclinical models . These antibodies function by blocking the LIF/LIFR interaction, thereby inhibiting downstream STAT3 phosphorylation. In vivo studies have shown that anti-LIF antibody treatment decreases p-STAT3 and Ki67 expression in tumor tissue while increasing cleaved caspase-3, indicating reduced proliferation and enhanced apoptosis. Furthermore, such treatment improves CD3+, CD4+, and CD8+ T cell infiltration in tumor tissues, suggesting immunomodulatory effects that contribute to tumor growth inhibition .

What role do LIF antibodies play in stem cell research?

LIF is a key regulator in maintaining the naive state of both human and mouse embryonic stem cells. Functional LIF antibodies can be used to modulate stem cell differentiation by interfering with the LIF signaling pathway. Recombinant human LIF (rhLIF) has been utilized to support stem cell proliferation and prevent differentiation . When investigating the effects of LIF on stem cell maintenance, neutralizing antibodies can serve as valuable tools to confirm pathway specificity. For experimental design, researchers commonly employ antibodies that specifically block LIF binding to LIFR, which disrupts downstream signaling while preserving other cytokine interactions .

How can researchers develop novel anti-LIF antibodies with specific antagonistic properties?

The development of antagonist antibodies targeting LIF involves several sophisticated techniques. One effective approach is screening single-chain variable fragments (scFvs) from naive human scFv phage libraries. These scFvs can then be reconstructed into complete IgG forms and produced using mammalian transient expression systems. For example, to develop antibody 1G11, researchers prepared human HEK293F cells at a density of 2×10^6 cells/mL and transfected them with recombinant antibody plasmids containing heavy and light chain sequences at a 1:1 ratio using linear PEI as a transfection reagent . Following expression, the antibodies can be purified by protein G affinity chromatography and characterized for binding specificity using techniques such as ELISA and surface plasmon resonance (SPR) .

What methods can be used to confirm the functional activity of anti-LIF antibodies?

Confirming the functional activity of anti-LIF antibodies requires a multi-faceted approach. Competitive ELISA can determine if antibodies interfere with LIF binding to its receptors (LIFR and gp130). For example, researchers have incubated antibodies with LIF-Fc fusion proteins and added them to microtiter plate wells coated with LIFR or gp130, using HRP-conjugated secondary antibodies to detect bound LIF-Fc . Additionally, Western blot analysis can assess the antibody's ability to inhibit LIF-induced STAT3 phosphorylation in relevant cell lines. The M1 growth inhibition assay represents another valuable functional test, where LIF potency is assessed by measuring the inhibition of M1 leukemia cell differentiation . A truly functional antagonist antibody would demonstrate dose-dependent inhibition of LIF-induced cellular responses.

What are the optimal conditions for using LIF antibodies in Western blot analyses?

For optimal Western blot detection of LIF using specific antibodies, researchers should consider several critical parameters. Sample preparation typically involves lysing cells in RIPA buffer supplemented with protease and phosphatase inhibitors, followed by protein quantification using Bradford or BCA assays. For gel electrophoresis, 10-15% polyacrylamide gels are recommended for resolving LIF (~20 kDa). Following transfer to nitrocellulose or PVDF membranes, blocking with 5% non-fat milk or BSA in TBST for 1 hour is advisable. Primary LIF antibodies are typically applied at dilutions ranging from 1:500 to 1:2000 (depending on the specific antibody) and incubated overnight at 4°C. After washing, appropriate HRP-conjugated secondary antibodies should be applied at 1:5000-1:10000 dilutions for 1 hour at room temperature . Enhanced chemiluminescence detection provides sensitive visualization of LIF expression patterns.

How should researchers design experiments to assess LIF signaling pathway inhibition by antagonist antibodies?

When designing experiments to evaluate the inhibitory effects of anti-LIF antibodies on LIF signaling, researchers should incorporate appropriate positive and negative controls alongside dose-response analyses. A comprehensive experimental design would include:

• Cell selection: Choose cell lines with verified expression of LIFR and gp130 (e.g., U266 and HCT116 cells).

• Dose-response: Test antibody concentrations ranging from 0.01-10 μg/ml to establish IC50 values.

• Time-course: Examine both acute (15-30 minutes) and sustained (24-48 hours) effects on signaling.

• Pathway analysis: Evaluate multiple pathway components including STAT3, ERK, and AKT phosphorylation.

• Functional readouts: Assess cellular outcomes such as proliferation, apoptosis, or differentiation .

Western blot analysis specifically examining phosphorylated STAT3 (Tyr705) levels represents a direct method to quantify pathway inhibition, as demonstrated with antibody 1G11 which achieves >90% inhibition of LIF-induced p-STAT3 at 2 μg/ml concentration .

What methods are recommended for evaluating LIF antibody specificity and cross-reactivity?

Thorough evaluation of LIF antibody specificity and cross-reactivity requires multiple complementary approaches. ELISA-based binding assays should be performed using purified recombinant LIF proteins from different species (human, mouse, monkey) to establish specificity profiles. Surface plasmon resonance (SPR) analysis provides detailed binding kinetics, including association and dissociation rates and equilibrium dissociation constants (KD). For example, antibody 1G11 demonstrated high-affinity binding to human LIF (KD = 3.80 × 10^-10 M), cynomolgus monkey LIF (KD = 1.15 × 10^-9 M), and mouse LIF (KD = 4.34 × 10^-10 M) .

Additional methods include competitive binding assays with related cytokines (IL-6, OSM, CNTF) to confirm specificity within the IL-6 family, and immunoprecipitation followed by mass spectrometry to identify any unintended targets. Western blot analysis using cell lysates from multiple species can verify cross-reactivity in complex biological samples, while immunohistochemistry on tissues from different species confirms reactivity in fixed specimens .

What are the key considerations when using LIF antibodies for immunohistochemistry (IHC) applications?

Successful immunohistochemical detection of LIF using specific antibodies requires careful optimization of several parameters. Tissue fixation should typically employ 10% neutral buffered formalin for 24-48 hours, followed by paraffin embedding and sectioning at 4-6 μm thickness. Antigen retrieval is critical and generally requires citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) treatment with heat induction (95-100°C for 15-20 minutes). Endogenous peroxidase should be blocked using 3% hydrogen peroxide for 10 minutes, followed by protein blocking with 5% normal serum for 30 minutes .

Primary LIF antibodies are typically applied at 1:100-1:500 dilutions and incubated overnight at 4°C in a humidified chamber. Detection systems may include biotin-streptavidin-HRP or polymer-based detection methods, with DAB as the chromogen. For multiplexed IHC, techniques such as sequential immunofluorescence or spectral unmixing can be employed to simultaneously visualize LIF alongside other markers such as p-STAT3, Ki67, or immune cell markers (CD3, CD4, CD8) as performed in tumor model studies with antibody 1G11 .

How should researchers interpret discrepancies between LIF protein detection and gene expression data?

When facing discrepancies between LIF protein levels (detected via antibody-based methods) and gene expression data (from qPCR or RNA-seq), researchers should consider several key factors that might explain these differences:

• Post-transcriptional regulation: LIF expression is heavily influenced by microRNAs and RNA-binding proteins that can affect mRNA stability and translation efficiency.

• Protein stability and turnover: LIF undergoes regulated degradation that may not correlate with transcript levels.

• Secretion dynamics: As a secreted protein, tissue LIF levels may not reflect local production if significant export occurs.

• Methodological limitations: Consider antibody specificity issues, detection sensitivity thresholds, and normalization methods.

To resolve such discrepancies, researchers should employ complementary approaches including pulse-chase experiments to assess protein turnover rates, analysis of secreted LIF in culture media or biological fluids, and evaluation of post-transcriptional regulatory mechanisms. Additionally, single-cell analyses can reveal heterogeneity within populations that might be masked in bulk measurements .

What controls should be included when evaluating the functional effects of LIF-blocking antibodies?

Rigorous experimental design for evaluating LIF-blocking antibodies should incorporate multiple controls:

• Isotype-matched control antibodies to rule out non-specific effects of antibody treatment

• Recombinant LIF protein as a positive control for pathway activation

• Small molecule STAT3 inhibitors as complementary pathway blockers

• siRNA/shRNA targeting LIF or LIFR to confirm target specificity

• Rescue experiments with excess LIF to demonstrate competitive inhibition

• Cell lines lacking LIFR expression as negative controls

For in vivo experiments, additional controls should include dosing-matched isotype control antibodies and careful monitoring of systemic effects through analysis of multiple tissues and cytokine profiling. When evaluating anti-tumor effects, measurements should include not only tumor volume but also changes in proliferation markers (Ki67), apoptosis indicators (cleaved caspase-3), signaling pathway activation (p-STAT3), and immune infiltration (CD3+, CD4+, CD8+ T cells) .

What are common technical challenges when working with LIF antibodies and how can they be addressed?

Researchers working with LIF antibodies may encounter several technical challenges that can be addressed through specific optimization strategies:

For functional blocking studies specifically, pre-incubation of antibodies with recombinant LIF before cell treatment can enhance consistency. Additionally, as demonstrated with antibody 1G11, understanding the specific epitope recognized (LIFR-binding region vs. gp130-binding region) can help predict functional outcomes and explain partial inhibition phenomena .

How can LIF antibodies be utilized in immunotherapy development?

LIF antibodies show considerable promise in cancer immunotherapy development through multiple mechanisms. Antagonist antibodies like 1G11 not only directly inhibit LIF-mediated tumor cell proliferation and survival but also modulate the tumor microenvironment to enhance anti-tumor immune responses. Research has demonstrated that anti-LIF antibody treatment increases infiltration of CD3+, CD4+, and CD8+ T cells in tumor tissues, suggesting a potential immunomodulatory effect that could complement existing immunotherapies .

Future immunotherapy applications may involve combining LIF-blocking antibodies with immune checkpoint inhibitors (anti-PD-1/PD-L1) to overcome immunosuppression in the tumor microenvironment. Additionally, bispecific antibodies targeting both LIF and immune cell activating receptors could provide dual targeting capabilities. For translational research, humanized versions of therapeutic LIF antibodies would need to be developed with careful evaluation of species cross-reactivity, as demonstrated by 1G11's ability to recognize human, cynomolgus monkey, and mouse LIF—an advantage for preclinical-to-clinical translation .

What is the potential of LIF antibodies in stem cell research and regenerative medicine?

LIF plays a crucial role in maintaining pluripotency in embryonic and induced pluripotent stem cells, particularly in mouse models. Researchers have employed recombinant human LIF (rhLIF) for the maintenance of stem cells in an undifferentiated state. Plant-based expression systems, such as rice-derived rhLIF, have demonstrated comparable specific activity to commercial sources, potentially offering cost-effective alternatives for large-scale stem cell culture .

LIF antibodies can serve as experimental tools to modulate stem cell differentiation by interfering with the LIF/LIFR/STAT3 signaling axis. By precisely controlling this pathway using neutralizing or blocking antibodies, researchers can investigate temporal requirements for LIF signaling during differentiation or reprogramming processes. Additionally, antibody-based depletion of LIF can facilitate directed differentiation protocols, while spatially controlled application of LIF antibodies in 3D culture systems could generate complex organoid structures with regionally specific cell types. Such applications could significantly advance personalized regenerative medicine approaches .